Cargando…

Plasma IAPP-Autoantibody Levels in Alzheimer’s Disease Patients Are Affected by APOE4 Status

Pancreas-derived islet amyloid polypeptide (IAPP) crosses the blood–brain barrier and co-deposits with amyloid beta (Aβ) in brains of type 2 diabetes (T2D) and Alzheimer’s disease (AD) patients. Depositions might be related to the circulating IAPP levels, but it warrants further investigation. Autoa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pocevičiūtė, Dovilė, Roth, Bodil, Schultz, Nina, Nuñez-Diaz, Cristina, Janelidze, Shorena, Olofsson, Anders, Hansson, Oskar, Wennström, Malin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960837/ https://www.ncbi.nlm.nih.gov/pubmed/36835187 http://dx.doi.org/10.3390/ijms24043776

Ejemplares similares

Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
por: Pocevičiūtė, Dovilė, et al.
Publicado: (2022)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Apolipoprotein E Interferes with IAPP Aggregation and Protects Pericytes from IAPP-Induced Toxicity
por: Gharibyan, Anna L., et al.
Publicado: (2020)

Contraction of human brain vascular pericytes in response to islet amyloid polypeptide is reversed by pramlintide
por: Nuñez-Diaz, Cristina, et al.
Publicado: (2023)

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype
por: Janelidze, Shorena, et al.
Publicado: (2017)

Levels of Retinal Amyloid-β Correlate with Levels of Retinal IAPP and Hippocampal Amyloid-β in Neuropathologically Evaluated Individuals
por: Schultz, Nina, et al.
Publicado: (2020)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Pro-Inflammatory Cytokines Reduce the Proliferation of NG2 Cells and Increase Shedding of NG2 In Vivo and In Vitro
por: Wennström, Malin, et al.
Publicado: (2014)

Mechanisms of Transthyretin Inhibition of IAPP Amyloid Formation
por: Wasana Jayaweera, Sanduni, et al.
Publicado: (2021)

Blood‐based biomarkers for Alzheimer's disease
por: Leuzy, Antoine, et al.
Publicado: (2021)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

Association of CSF Aβ(38) Levels With Risk of Alzheimer Disease–Related Decline
por: Cullen, Nicholas, et al.
Publicado: (2022)

β-Amyloid–Dependent and –Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease
por: Kumar, Atul, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

Towards a unified protocol for handling of CSF before β-amyloid measurements
por: Janelidze, Shorena, et al.
Publicado: (2019)

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2018)

Brain alpha‐amylase: a novel energy regulator important in Alzheimer disease?
por: Byman, Elin, et al.
Publicado: (2018)

The implications of different approaches to define AT(N) in Alzheimer disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

α-synuclein−lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients
por: Paslawski, Wojciech, et al.
Publicado: (2019)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2019)

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Amyloid‐beta 1‐40 is associated with alterations in NG2+ pericyte population ex vivo and in vitro
por: Schultz, Nina, et al.
Publicado: (2018)

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
por: Whelan, Christopher D., et al.
Publicado: (2019)

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Cerebrospinal fluid concentrations of inflammatory markers in Parkinson’s disease and atypical parkinsonian disorders
por: Hall, Sara, et al.
Publicado: (2018)

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes
por: Ygland Rödström, Emil, et al.
Publicado: (2022)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Correction: Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217
por: Groot, Colin, et al.
Publicado: (2022)

Autoantibodies and gastrointestinal symptoms in infertile women in relation to in vitro fertilization
por: Hammar, Oskar, et al.
Publicado: (2013)

Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms
por: Arvidsson, Ida, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ga0anumf46mqv7mveanqpb4k3j